This OncView program features content experts who share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma (RCC) and comment on emerging data in the field.
EP. 12: Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended RegimensApril 18th 2022
David Aggen, MD, PhD identifies patient populations who may benefit from single-agent therapy and reviews NCCN recommendations for first-line treatment of metastatic clear cell RCC.
EP. 13: Safety and Efficacy Data: The CheckMate 214 Trial
Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.
EP. 14: Safety and Efficacy Data: The JAVELIN Renal 101 Trial
Chung-Han Lee, MD, PhD, discusses data from the JAVELIN Renal 101 trial of axitinib/avelumab versus sunitinib in metastatic RCC.
EP. 18: Common Adverse Events with Single-Agent or Combination Therapy
Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.
EP. 19: Balancing Treatment Efficacy with Toxicity in Metastatic RCC
David Aggen, MD, PhD, describes the challenges of balancing treatment efficacy versus toxicity and tolerability in patients with kidney cancer.
EP. 20: Strategies for Prevention and Management of Adverse Events
Chung-Han Lee, MD, PhD, provides a commentary on strategies for preventing and managing treatment-related adverse events in metastatic RCC.
EP. 21: Patient-Specific Factors Impacting Treatment Choices in RCC
Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.
EP. 22: Considerations for Patient-Focused, Shared Decision-Making in RCC
Chung-Han Lee, MD, PhD, delves into clinical and logistical factors that influence patient-focused, shared-decision making for those with metastatic RCC.
EP. 23: Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.
EP. 24: The Importance of Team-Based Management and Patient Communication
Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.
EP. 25: OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.
EP. 26: Reflections on Novel Targets and Emerging Regimens for RCC
Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.
EP. 27: Clinical Pearls on Recent Advances and the Future of Treatment in RCC
Mehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.